Skip to main content

Advertisement

Table 1 Pre-defined inclusion and exclusion criteria

From: Effect of intravitreal aflibercept on recalcitrant diabetic macular edema

Inclusion criteria
 Able to provide informed consent
 Age 18 years or older
 Clear ocular media
 Baseline IOP of 21 mmHg or less with or without pressure-lowering drops in patients previously treated with corticosteroids
 Snellen visual acuity between 20/40 and 20/300
 CRT on SD-OCT ≥350 μm at the time of switch to IVE
 Minimum of 4 treatments for DME, with at least 3 being anti-VEGF intravitreal injections (excluding IAI), administered within the 6 months prior to IAI switch
 <15% decrease in CRT during the 6 months prior to IAI switch (worsening)
 3 or more IAI within 6 months after switch
Exclusion criteria
 Previous IAI in the study eye
 History of systemic anti-VEGF use